228
Participants
Start Date
January 29, 2024
Primary Completion Date
February 28, 2026
Study Completion Date
February 28, 2026
DB-1303/BNT323
Administered I.V.
T-DM1
Administered I.V.
001, Beijing
010, Beijing
032, Dalian
008, Changchun
038, Jilin
020, Haerbin
002, Shanghai
046, Shanghai
027, Nanjing
004, Nanjing
044, Xuzhou
016, Hefei
029, Hefei
015, Bengbu
031, Jinan
047, Jinan
040, Binzhou
039, Yantai
012, Linyi
021, Tianjin
025, Hangzhou
042, Hangzhou
019, Hangzhou
014, Nanchang
036, Fuzhou
037, Xiamen
030, Changsha
011, Wuhan
009, Wuhan
006, Zhengzhou
005, Zhengzhou
018, Luoyang
023, Guangzhou
024, Guangzhou
026, Guangzhou
028, Huizhou
017, Nanning
022, Nanning
043, Haikou
007, Chengdu
041, Neijiang
034, Yibin
033, Kunming
003, Xi’an
013, Ürümqi
045, Baoding
048, Shijiazhuang
035, Taiyuan
Collaborators (1)
BioNTech SE
INDUSTRY
DualityBio Inc.
INDUSTRY